Arkolith/Insider Trading/LYEL/Form 4

Bulis Veronica Sanchez

VP, Corporate ControllerLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Jan 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$74K
Net Open-Market Flow
-$74K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 30, 2025Sell(S)936$32.32$30K7K
Dec 24, 2025Sell(S)1K$38.67$44K8K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002095702-26-000001) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML